PFS by response and MRD status among patients who received daratumumab-based regimens vs control regimens. PFS by response and MRD status (10⁻⁵) among patients in the pooled daratumumab-combination groups vs the pooled control groups from POLLUX, CASTOR, ALCYONE, and MAIA who achieved CR or better and were MRD negative (≥CR and MRD negative) or who achieved a response less than CR or were MRD positive (≤VGPR or MRD positive) for all patients combined (A) and patients in POLLUX and CASTOR with ≤2 PL pooled with all patients from ALCYONE and MAIA (B). Shown are Kaplan-Meier estimates of PFS among patients in the ITT population based on the absence of MRD as measured using the threshold of 1 tumor cell per 10⁵ white cells and response categories according to IMWG criteria. In CASTOR and ALCYONE, standard of care was given for a fixed number of cycles and daratumumab was given until disease progression. In POLLUX and MAIA, patients who received standard of care or daratumumab-based regimens received study treatment until disease progression or unacceptable toxicity. Dara, daratumumab.